BACKGROUND: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent low-grade glioma to measure sustained response and/or stable disease lasting ≥6 months and progression-free survival. METHODS: Thirty-five evaluable patients received 2 doses (10 mg/kg each) of single-agent BVZ intravenously 2 weeks apart and then BVZ + CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included neuroimaging and expression of tumor angiogenic markers (vascular endothelial growth factor [VEGF], VEGF receptor 2, hypoxia-inducible factor 2α, and carbonic anhydrase 9). RESULTS: Thirty-five evaluable patients (median age 8.4 y [range, 0.6-17.6]) received a median of 12 courses of BVZ + CPT-11 (range, 2-26). Twenty-nine of 35 patients (83%) received treatment for at least 6 months. Eight patients progressed on treatment at a median time of 5.4 months (range, 1-17.8). Six patients (17.7%) still in follow-up have had stable disease without receiving additional treatment for a median of 40.1 months (range, 30.6-49.3) from initiating therapy. The 6-month and 2-year progression-free survivals were 85.4% (SE ± 5.96%) and 47.8% (SE ± 9.27%), respectively. The commonest toxicities related to BVZ included grades 1-2 hypertension in 24, grades 1-2 fatigue in 23, grades 1-2 epistaxis in 18, and grades 1-4 proteinuria in 15. The median volume of enhancement decreased significantly between baseline and day 15 (P < .0001) and over the duration of treatment (P < .037). CONCLUSION: The combination of BVZ + CPT-11 appears to produce sustained disease control in some children with recurrent low-grade gliomas.
BACKGROUND: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent low-grade glioma to measure sustained response and/or stable disease lasting ≥6 months and progression-free survival. METHODS: Thirty-five evaluable patients received 2 doses (10 mg/kg each) of single-agent BVZ intravenously 2 weeks apart and then BVZ + CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included neuroimaging and expression of tumor angiogenic markers (vascular endothelial growth factor [VEGF], VEGF receptor 2, hypoxia-inducible factor 2α, and carbonic anhydrase 9). RESULTS: Thirty-five evaluable patients (median age 8.4 y [range, 0.6-17.6]) received a median of 12 courses of BVZ + CPT-11 (range, 2-26). Twenty-nine of 35 patients (83%) received treatment for at least 6 months. Eight patients progressed on treatment at a median time of 5.4 months (range, 1-17.8). Six patients (17.7%) still in follow-up have had stable disease without receiving additional treatment for a median of 40.1 months (range, 30.6-49.3) from initiating therapy. The 6-month and 2-year progression-free survivals were 85.4% (SE ± 5.96%) and 47.8% (SE ± 9.27%), respectively. The commonest toxicities related to BVZ included grades 1-2 hypertension in 24, grades 1-2 fatigue in 23, grades 1-2 epistaxis in 18, and grades 1-4 proteinuria in 15. The median volume of enhancement decreased significantly between baseline and day 15 (P < .0001) and over the duration of treatment (P < .037). CONCLUSION: The combination of BVZ + CPT-11 appears to produce sustained disease control in some children with recurrent low-grade gliomas.
Authors: Christopher Calabrese; Helen Poppleton; Mehmet Kocak; Twala L Hogg; Christine Fuller; Blair Hamner; Eun Young Oh; M Waleed Gaber; David Finklestein; Meredith Allen; Adrian Frank; Ildar T Bayazitov; Stanislav S Zakharenko; Amar Gajjar; Andrew Davidoff; Richard J Gilbertson Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: H S Friedman; W P Petros; A H Friedman; L J Schaaf; T Kerby; J Lawyer; M Parry; P J Houghton; S Lovell; K Rasheed; T Cloughsey; E S Stewart; O M Colvin; J M Provenzale; R E McLendon; D D Bigner; I Cokgor; M Haglund; J Rich; D Ashley; J Malczyn; G L Elfring; L L Miller Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Anuradha Banerjee; Roger J Packer; Lindsay B Kilburn; Stewart Goldman; Ian F Pollack; Ibrahim Qaddoumi; Regina I Jakacki; Paul G Fisher; Girish Dhall; Patricia Baxter; Susan G Kreissman; Clinton F Stewart; David T W Jones; Stefan M Pfister; Gilbert Vezina; Jessica S Stern; Ashok Panigrahy; Zoltan Patay; Benita Tamrazi; Jeremy Y Jones; Sofia S Haque; David S Enterline; Soonmee Cha; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi Journal: Lancet Oncol Date: 2019-05-28 Impact factor: 41.316
Authors: R C Brennan; W Furman; S Mao; J Wu; D C Turner; C F Stewart; V Santana; L M McGregor Journal: Cancer Chemother Pharmacol Date: 2014-09-26 Impact factor: 3.333
Authors: Christopher H Hsu; Robert M Lober; Matthew D Li; Sonia Partap; Patricia A Murphy; Patrick D Barnes; Paul G Fisher; Kristen W Yeom Journal: J Neurooncol Date: 2015-03-11 Impact factor: 4.130
Authors: Mark W Kieran; Susan Chi; Stewart Goldman; Arzu Onar-Thomas; Tina Young Poussaint; Sridhar Vajapeyam; Frederic Fahey; Shengjie Wu; David C Turner; Clinton F Stewart; Marsha Moses; Roger J Packer; Regina Jakacki; Anu Banerjee; James M Boyett; Maryam Fouladi; Larry Kun Journal: Childs Nerv Syst Date: 2015-07-19 Impact factor: 1.475
Authors: Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran Journal: Biochim Biophys Acta Date: 2014-02-28